Evidence map›Paper›PMID 38336940›Full record

ArticleActa neuropathologica communications2024

Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease.

Ana-Caroline Raulin, Sydney V Doss, Michael G Heckman, Emily C Craver, Zonghua Li, Tadafumi C Ikezu, Hiroaki Sekiya, Chia-Chen Liu, Yuka A Martens, Cassandra L Rosenberg and 12 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 2 countries.

Ana-Caroline RaulinDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Sydney V DossDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Michael G HeckmanDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, 32224, USA.
Emily C CraverDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, 32224, USA.
Zonghua LiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Tadafumi C IkezuDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, 32224, USA.
Hiroaki SekiyaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Chia-Chen LiuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Yuka A MartensDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Cassandra L RosenbergDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Lindsey A KuchenbeckerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Michael DeTureDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
R Ross ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Aivi T NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Eleni ConstantopoulosDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Rachel A LarsenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Emmaline K KounavesDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, 55905, USA.
Guojun BuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.
Takahisa KanekiyoDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA. kanekiyo.takahisa@mayo.edu.ORCID 0000-0001-6751-9374
Mayo Clinic in Florida · USMayo Clinic in Arizona · USBiogen (United States) · USHong Kong University of Science and Technology · HKJacksonville College · USMayo Clinic · US

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI Celeste Marie Karch · 2021 to 2026
$42.0M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Impact of ApoE2 on aging-related conditionsRF1AG057181 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2018 to 2018
$3.7M
Neuronal ABCA7 loss of function and Alzheimer’s diseaseRF1AG081203 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2023 to 2023
$2.1M
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's DiseaseRF1AG068034 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2021 to 2022
$1.6M
Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementiaRF1AG071226 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2021 to 2021
$1.2M
Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementiaR01AG071226 · NIA · MAYO CLINIC JACKSONVILLE · PI KANEKIYO, TAKAHISA · 2024 to 2025
$775k
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG071226NIA NIH HHS RF1 AG057181NIA NIH HHS RF1 AG068034NIA NIH HHS RF1 AG071226NIA NIH HHS RF1 AG081203NIA NIH HHS U01 AG006786NIA NIH HHS U19 AG069701
6 · The paper itself

Abstract

Alzheimer's disease (AD), characterized by the deposition of amyloid-β (Aβ) in senile plaques and neurofibrillary tangles of phosphorylated tau (pTau), is increasingly recognized as a complex disease with multiple pathologies. AD sometimes pathologically overlaps with age-related tauopathies such as four repeat (4R)-tau predominant argyrophilic grain disease (AGD). While AGD is often detected with AD pathology, the contribution of APOE4 to AGD risk is not clear despite its robust effects on AD pathogenesis. Specifically, how APOE genotype influences Aβ and tau pathology in co-occurring AGD and AD has not been fully understood. Using postmortem brain samples (N = 353) from a neuropathologically defined cohort comprising of cases with AD and/or AGD pathology built to best represent different APOE genotypes, we measured the amounts of major AD-related molecules, including Aβ40, Aβ42, apolipoprotein E (apoE), total tau (tTau), and pTau181, in the temporal cortex. The presence of tau lesions characteristic of AD (AD-tau) was correlated with cognitive decline based on Mini-Mental State Examination (MMSE) scores, while the presence of AGD tau lesions (AGD-tau) was not. Interestingly, while APOE4 increased the risk of AD-tau pathology, it did not increase the risk of AGD-tau pathology. Although APOE4 was significantly associated with higher levels of insoluble Aβ40, Aβ42, apoE, and pTau181, the APOE4 effect was no longer detected in the presence of AGD-tau. We also found that co-occurrence of AGD with AD was associated with lower insoluble Aβ42 and pTau181 levels. Overall, our findings suggest that different patterns of Aβ, tau, and apoE accumulation mediate the development of AD-tau and AGD-tau pathology, which is affected by APOE genotype.

Indexed as

Alzheimer DiseaseApolipoproteins ETauopathiesAmyloidAmyloid beta-PeptidesApolipoprotein E4Humanstau ProteinsAmyloidAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins Etau ProteinsAlzheimer’s diseaseAmyloid-βApolipoprotein EArgyrophilic grain diseaseMMSETau

Identifiers

PMID38336940
PMCPMC10854035
OpenAlexW4391685637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.